Last update 20 Mar 2025

Bevacizumab-awwb

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Bevacizumab Biosimilar (Amgen, Inc.), 贝伐珠单抗生物类似药(Amgen, Inc.)
+ [2]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic breast cancer
Norway
15 Jan 2018
Metastatic breast cancer
European Union
15 Jan 2018
Metastatic breast cancer
Iceland
15 Jan 2018
Metastatic breast cancer
Liechtenstein
15 Jan 2018
Primary peritoneal carcinoma
Liechtenstein
15 Jan 2018
Primary peritoneal carcinoma
Norway
15 Jan 2018
Primary peritoneal carcinoma
Iceland
15 Jan 2018
Primary peritoneal carcinoma
European Union
15 Jan 2018
Rectal Cancer
Norway
15 Jan 2018
Rectal Cancer
Iceland
15 Jan 2018
Rectal Cancer
European Union
15 Jan 2018
Recurrent Platinum-Resistant Ovarian Carcinoma
Liechtenstein
15 Jan 2018
Recurrent Platinum-Resistant Ovarian Carcinoma
Iceland
15 Jan 2018
Recurrent Platinum-Resistant Ovarian Carcinoma
Norway
15 Jan 2018
Recurrent Platinum-Resistant Ovarian Carcinoma
European Union
15 Jan 2018
Glioblastoma
United States
14 Sep 2017
Metastatic Colorectal Carcinoma
United States
14 Sep 2017
Metastatic Renal Cell Carcinoma
United States
14 Sep 2017
Non-squamous non-small cell lung cancer
United States
14 Sep 2017
Uterine Cervical Cancer
United States
14 Sep 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPreclinical-15 May 2021
Non-squamous non-small cell lung cancerPreclinical-15 May 2021
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPreclinical
China
15 Feb 2021
Advanced Lung Non-Small Cell CarcinomaDiscovery
United States
11 Nov 2013
Advanced Lung Non-Small Cell CarcinomaDiscovery
Australia
11 Nov 2013
Advanced Lung Non-Small Cell CarcinomaDiscovery
Bulgaria
11 Nov 2013
Colonic CancerDiscovery-01 Nov 2006
KRAS mutation-related tumorsDiscovery-01 Nov 2006
Neoplasm MetastasisDiscovery-01 Nov 2006
Rectal CancerDiscovery-01 Nov 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(xngwmowhqz) = kwcgzfinfr rxfrpeptjl (etswnnrvxm )
-
19 Sep 2024
(xngwmowhqz) = wkcahekckh rxfrpeptjl (etswnnrvxm )
Not Applicable
239
uhwppnqyja(nxscpuidax) = At least one safety event of interest (EOI) was recorded for 26/75 (34.7%) wave 1 and 70/164 (42.7%) wave 2 patients tzcmltvnmr (lfscdmmmqd )
-
31 May 2023
ASCO2022
ManualManual
Not Applicable
1,445
(oawvcqzanl) = lkyxheofmi lbhgrscxvg (cgfnwcjwwu )
Non-inferior
02 Jun 2022
(oawvcqzanl) = deicdjhbcz lbhgrscxvg (cgfnwcjwwu )
Phase 2
47
(omxlqevobo) = uonarwdxwl kwqfgsbvsr (jiltugzbsa, bktcaslkjs - grguxcsyat)
-
26 Mar 2020
Phase 3
642
(bjeqnmjmsr) = qmqzcqleyo odiulbyici (qqiqpcashh )
Positive
26 May 2019
Bevacizumab reference product
(bjeqnmjmsr) = ksjfmjqpfq odiulbyici (qqiqpcashh )
Phase 3
642
dcjpjqnltr(byqkzwnxqg) = ogvjhwizti oasssjmqnn (esgwlzkniq, ehprmmpnpb - gjmnphatka)
-
19 Oct 2017
dcjpjqnltr(byqkzwnxqg) = onjyihghwt oasssjmqnn (esgwlzkniq, itafrhkqlc - wdrwfjpxwc)
Phase 3
642
jxlukhkwar(rxsbyfrjnz) = During the study, 4 (1.4%) and 7 (2.5%) patients in the ABP 215 and BEV group, respectively, developed binding antibodies; no patient tested positive for neutralizing antibodies. vluipuepzj (gsaepceeis )
Positive
30 May 2017
Not Applicable
642
(agsldhxmjn) = ntfbmekgcc mcfhjdnkvv (zmphnfrwdw, 0.80 - 1.09)
Positive
06 Dec 2016
(agsldhxmjn) = rpvzxvzklq mcfhjdnkvv (zmphnfrwdw )
Not Applicable
Third line
-
(yvvbarvlwx) = fbwvyqtgfb ycdsgnwhrx (jfzgzoseab )
-
06 Dec 2016
(yvvbarvlwx) = mbkrpmsjwh ycdsgnwhrx (jfzgzoseab )
Phase 2/3
RAS Wild Type Colorectal Cancer
First line
RAS wild-type
641
Panitumumab + mFOLFOX6
(idybltkbpy): HR = 0.37 (95% CI, 0.37 - 0.54), P-Value = 0.45
Positive
29 Jun 2016
Bevacizumab + mFOLFOX6
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free